Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01897532 · ClinicalTrials.gov registry record · Phase 4
Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)
A Phase 4 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 4
- Development phase
- 6,991
- Enrollment target
NCT01897532 is a Phase 4 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 6,991 participants.
The verdict
NCT01897532, a Phase 4 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 6,991 participants
- Enrollment target
Study Summary
The aim of the study is to investigate the longterm impact on cardiovascular morbidity, mortality and renal function of treatment with linagliptin in a selected population of patients with Type 2 diabetes mellitus (T2DM) and to compare outcomes against placebo, on a background of standard of care.
Interventions
- DRUG Placebo
- DRUG Linagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,991 participants |
| Start Date | 2013-07-10 |
| Est. Completion | 2018-01-18 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01897532
The ClinicalTrials.gov registry entry for NCT01897532 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 6,991 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01897532 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01897532 about?
NCT01897532 is a clinical study titled "Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)". The aim of the study is to investigate the longterm impact on cardiovascular morbidity, mortality and renal function of treatment with linagliptin in a selected population of patients with Type 2 diabetes mellitus (T2DM) and to compare outcomes against placebo, on a background of standard of care.
What is the current status of trial NCT01897532?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 6,991 participants. The study started on 2013-07-10. Estimated completion is 2018-01-18.
What interventions are being tested in trial NCT01897532?
The interventions under investigation include: Placebo (DRUG), Linagliptin (DRUG).
Who is sponsoring clinical trial NCT01897532?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.